Protara Therapeutics (TARA) Interest & Investment Income (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Interest & Investment Income of -$454000.0 for Q1 2026, down 621.84% year-over-year from $87000.0 in Q1 2025, and down 756.6% quarter-over-quarter from -$53000.0 in Q4 2025.
Powered by 
Analysis
Protara Therapeutics (TARA) Interest & Investment Income (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Interest & Investment Income for 13 consecutive years, with -$454000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income fell 621.84% year-over-year to -$454000.0; the TTM figure through Mar 2026 stood at -$82000.0 (down 101.81% YoY), while the FY2025 annual figure was $88000.0, down 97.35% from the prior year.
- Interest & Investment Income declined to -$454000.0 in Q1 2026 per TARA's latest filing, from -$53000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $3.3 million in Q4 2024 and bottomed at -$1.7 million in Q4 2023.
- Historically, Interest & Investment Income has averaged $200058.8 across 5 years, with a median of $68000.0 in 2024.
- Annual changes were most pronounced in 2023 — Interest & Investment Income sank 687.16% — and 2025, when it surged 1406.9%.
- Protara Therapeutics' Interest & Investment Income stood at -$218000.0 in 2022, then tumbled by 687.16% to -$1.7 million in 2023, then surged by 290.33% to $3.3 million in 2024, then tumbled by 101.62% to -$53000.0 in 2025, then plunged by 756.6% to -$454000.0 in 2026.
- Business Quant data shows TARA's Interest & Investment Income at -$454000.0 in Q1 2026, -$53000.0 in Q4 2025, and $437000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Protara Therapeutics | 241.28 Mn | 241.28 Mn | - | 1.66 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.66 Mn |
| Mar 31, 2026 | 1.85 Mn |
| Dec 31, 2025 | 1.52 Mn |
| Sep 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 1.63 Mn |
| Mar 31, 2025 | 1.73 Mn |
| Dec 31, 2024 | 1.16 Mn |
| Sep 30, 2024 | 1.11 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 756,000.00 |
| Dec 31, 2023 | 820,000.00 |
| Sep 30, 2023 | 840,000.00 |
| Jun 30, 2023 | 846,000.00 |
| Mar 31, 2023 | 687,000.00 |
| Dec 31, 2022 | 632,000.00 |
| Sep 30, 2022 | 557,000.00 |
| Jun 30, 2022 | -180,000.00 |
| Mar 31, 2022 | -731,000.00 |
| Dec 31, 2021 | 59,000.00 |
| Sep 30, 2021 | 62,000.00 |